Mexico has consolidated itself as a strategic market for Bayer on a global scale by concentrating a significant part of its pharmaceutical innovation and production capacity in the country. Daniel Londero, General Manager of Bayer Pharma in the country, stated this in an interview with Publimetro. According to the executive, nearly 90% of the innovation developed by the company worldwide reaches the country, positioning Mexico as one of the main operational centers in Latin America. He also highlighted that the country has three pharmaceutical production plants that export medicines to more than 40 countries, including the United States, Canada, and European nations.
Boost to Clinical Research and New Treatments In terms of innovation, the company has increased its presence in clinical research, with at least 10 active studies in more than 40 medical centers and the participation of over 200 patients. Londero noted that the expectation is to double or even triple these studies in the coming years, which would allow for greater patient access to innovative treatments. Among recent advances, he highlighted the incorporation of new therapies for prostate cancer, diabetes-associated chronic kidney disease, and hemophilia, some of which are already part of the public health system.
Access to Medicines, the Main Challenge The executive emphasized that one of the biggest challenges in the Mexican health system is ensuring access to treatments, which is why the company maintains constant dialogue with authorities to facilitate the adoption of new therapies. He explained that prevention through timely treatments can generate savings for the health system by avoiding complications such as dialysis or transplants in chronic diseases.
Priorities: Chronic Diseases and Women's Health Bayer plans to focus its efforts on areas such as cardiovascular and renal diseases, oncology, central nervous system disorders, rare diseases, and women's health. The company is also working on the approval of new therapeutic indications and treatments, including options for heart failure and menopause.
Investment and Patient Impact Goal The company announced an investment of 3 billion pesos in the country, mainly in productive infrastructure, and to strengthen its presence in clinical research. As part of its strategy, Bayer aims to benefit more than 10 million patients in Mexico by 2026 through access to its treatments.
Pharmaceutical Industry and Life Expectancy Londero highlighted that the development of medicines has significantly contributed to the increase in life expectancy, pointing out that a relevant part of this advance is due to innovation in treatments. In this context, he defended the role of the pharmaceutical industry as a key actor for improving the quality and duration of life of the population. The company, he added, maintains a long-term vision in Mexico, where it has operated for over a century and plans to continue its expansion in the coming years.
